Form 1 Proteomics Data Commons Data (PDC)

Attachment 1: Proteomic Data Commons Data Submission Request Form

OMB No.: 0925-0775
Expiration Date: 06/30/2025

Collection of this information is authorized by The Public Health Service Act, Section 411 (42 USC 285a). Rights of participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing at any time. Refusal to participate will not affect your benefits in any way. The information collected will be kept private to the extent provided by law. Names and other identifiers will not appear in any report. Information provided will be combined for all participants and reported as summaries. You are being contacted online to complete this form so that NCI can consider your study for submission into the Proteomic Data Commons.

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0775). Do not return the completed form to this address.

Please complete the following document and send to: PDCHelpDesk@mail.nih.gov.

Please include a narrative describing your study and its scientific benefit for inclusion in the Proteomic Data Commons (PDC).

Please include the following information:

1. Name/Identifier of Study with a brief description

2. Grant ID and funding source (if applicable)

3. IRB approval numbers (if applicable)

4. Scientific Point of Contact (Name, Phone, Email)

5. Data Manager Point of Contact (Name, Phone, Email)

6. Data access policy (choose one):

1. Open-access – no-embargo

2. Open-access – embargo

7. Cancer type(s) included in study

8. Number of cases included in study (please indicate if demographic and diagnosis data are available)

9. Information on the Proteomic Data Analysis Protocol

1. Type of acquisition – DDA, DIA

2. Experiment type – Label Free, iTRAQ, TMT, etc.

3. Analytical fractions – Proteome, phosphoproteome, etc.

4. Instrument make and model

5. Additional proteomic data analysis protocol including experimental design

10. Additional data types included in study and experimental strategies used (list all that apply and indicate target repository for additional data types such as the National Cancer Institute’s Genomic Data Commons):

1. Imaging

2. Genomics

3. Immunology

4. Clinical

5. Other (specify)

11. Amount of data (in TB, # of files)

12. Include description of treatment, relapse/recurrence, and/or outcome data available with this dataset (if applicable)

13. The overall scientific benefit of including this study in the PDC

14. Publications associated with this study, if any.

15. Time constraints on processing/loading/releasing the data to the public

16. Data standards used, if any.

Please attach (if available):

1. Data Dictionary

2. Biospecimen and experiment metadata

3. Data Model/Schema diagram indicating how collected data relates to subjects, visits, samples, etc.

1